Clinical issues in considering vagus nerve stimulation for treatment-resistant depression

Experimental Neurology

Volumn 219, Issue 1, 2009, Pages 36-43

  Rush, A John ^a   Siefert, Susan E ^b  

^a DUKE NUS MEDICAL SCHOOL   (Singapore)

^b Cyberonics Inc   (Italy)

Author keywords

Treatment resistant depression; Vagus nerve stimulation (VNS)

Indexed keywords

LITHIUM SALT; NORTRIPTYLINE;

CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMPARATIVE STUDY; DEPRESSION; DISEASE COURSE; ELECTROCONVULSIVE THERAPY; EPILEPSY; HUMAN; LONG TERM CARE; NEUROTRANSMISSION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RELAPSE; REMISSION; REVIEW; TREATMENT INDICATION; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE; VAGUS NERVE STIMULATION;

AFFERENT PATHWAYS; ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER; DRUG RESISTANCE; ELECTRIC STIMULATION THERAPY; HUMANS; PATIENT SELECTION; TREATMENT OUTCOME; VAGUS NERVE;

EID: 68649127297     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2009.04.015     Document Type: Review

References (47)

1. Ben-Menachem E., Hamberger A., Hedner T., Hammond E.J., Uthman B.M., Slater J., Treig T., Stefan H., Ramsay R.E., Wernicke J.F., and Wilder B.J. Effects of vagus nerve stimulation on amino acids and other metabolites in the CSF of patients with partial seizures. Epi. Res. 20 (1995) 221-227
2. Bernard E.J., Passannante A.N., Mann B., Lannon S., and Vaughn B.V. Insertion of vagal nerve stimulator using local and regional anesthesia. Surg. Neurol. 57 (2002) 94-98
3. Bewick V., Cheek L., and Ball J. Statistic review 11: assessing risk. Critical Care 8 (2004) 287-291
4. Conway C.R., Sheline Y.I., Chibnall J.T., George M.S., Fletcher J.W., and Mintun M.A. Cerebral blood flow changes during vagus nerve stimulation for depression. Psychiatry Res. 146 (2006) 179-184
5. Crismon M.L., Trivedi M., Pigott T.A., Rush A.J., Hirschfeld R.M., Kahn D.A., DeBattista C., Nelson J.C., Nierenberg A.A., Sackeim H.A., Thase M.E., and Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder. The Texas medication algorithm project: report of the Texas consensus conference panel on medication treatment of major depressive disorder. J. Clin. Psychiatry 60 (1999) 142-156
6. Cunningham J.T., Mifflin S.W., Gould G.G., and Frazer A. Induction of c-Fos and DeltaFosB immunoreactivity in rat brain by vagal nerve stimulation. Neuropsychopharmacology 33 (2008) 1884-1895
7. Dorr A.E., and Debonnel G. Effect of vagus nerve stimulation on serotonergic and noradrenergic transmission. J. Pharmacol. Exp. Ther. 318 (2006) 890-898
8. Dunner D.L., Rush A.J., Russell J.M., Burke M., Woodard S., Wingard P., and Allen J. Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. J. Clin. Psychiatry 67 (2006) 688-695
9. Fava M., Rush A.J., Trivedi M.H., Nierenberg A.A., Thase M.E., Sackeim H.A., Quitkin F.M., Wisniewski S., Lavori P.W., Rosenbaum J.F., Kupfer D.J., and STAR*D Investigators Group. Background and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. Psychiatr. Clin. N. Am. 26 (2003) 457-494
10. Fava M., Rush A.J., Wisniewski S.R., Nierenberg A.A., Alpert J.E., McGrath P.J., Thase M.E., Warden D., Biggs M., Luther J.F., Niederehe G., Ritz L., and Trivedi M.H. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am. J. Psychiatry 163 (2006) 1161-1172
11. Frederikse M., Petrides G., and Kellner C. Continuation and maintenance electroconvulsive therapy for the treatment of depressive illness: a response to the National Institute for Clinical Excellence report. J. ECT, 22 (2006) 13-17
12. George M.S., Sackeim H.A., Rush A.J., Marangell L.B., Nahas Z., Husain M.M., Lisanby S., Burt T., Goldman J., and Ballenger J.C. Vagus nerve stimulation: a new tool for brain research and therapy. Biol. Psychiatry 47 (2000) 287-295
13. George M.S., Rush A.J., Marangell L.B., Sackeim H.A., Brannan S.K., Davis S.M., Howland R., Kling M.A., Moreno F., Rittberg B., Dunner D., Schwartz T., Carpenter L., Burke M., Ninan P., and Goodnick P. A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol. Psychiatry. 58 (2005) 364-373
14. Hagen, M.C., Sheikh, S., Adson, D., Rittberg, B., Abussahab, F.S., Lee, J.T., Pardo, J.V., 2003. Metabolic changes in treatment-resistant depression responsive to VNS Therapy. Poster presented at the 58th Annual Scientific Convention of the Society of Biological Psychiatry, May 15-17, 2003, San Francisco, California.
15. Harden C.L., Pulver M.C., Ravdin L.D., Nikolov B., Halper J.P., and Labar D.R. A pilot study of mood in epilepsy patients treated with vagus nerve stimulation. Epilepsy Behav. 1 (2000) 93-99
16. Henry T.R., Bakay R.A., Votaw J.R., Pennell P.B., Epstein C.M., Faber T.L., Grafton S.T., and Hoffman J.M. Brain blood flow alterations induced by therapeutic vagus nerve stimulation in partial epilepsy: I. Acute effects at high and low levels of stimulation. Epilepsia 39 (1998) 983-990
17. Kellner C.H., Knapp R.G., Petrides G., Rummans T.A., Husain M.M., Rasmussen K., Mueller M., Bernstein H.J., O, Connor K., Smith G., Biggs M., Bailine S.H., Malur C., Yim E., McClintock S., Sampson S., and Fink M. Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression. Arch. Gen. Psychiatry 63 (2006) 1337-1344
18. Krahl S.E., Senanayake S.S., Pekary A.E., and Sattin A. Vagus nerve stimulation (VNS) is effective in a rat model of antidepressant action. J. Psychiatr. Res. 38 (2004) 237-240
19. Kwan P., and Brodie M.J. Early identification of refractory epilepsy. N. Engl. J. Med. 342 (2000) 314-319
20. Landy H.J., Ramsay R.E., Slater J., Casiano R.R., and Morgan R. Vagus nerve stimulation for complex partial seizures: surgical technique, safety, and efficacy. J. Neurosurg. 78 (1993) 26-31
21. Lisanby S.H., Maddox J.H., Prudic J., Devanand D.P., and Sackeim H.A. The effects of electroconvulsive therapy on memory of autobiographical and public events. Arch. Gen. Psychiatry 57 (2000) 581-590
22. Marangell L.B., Rush A.J., George M.S., Sackeim H.A., Johnson C.R., Husain M.M., Nahas Z., and Lisanby S.H. Vagus nerve stimulation (VNS) for major depressive episodes one year outcomes. Biol. Psychiatry 51 (2002) 280-287
23. McGrath P.J., Stewart J.W., Fava M., Trivedi M.H., Wisniewski S.R., Nierenberg A.A., Thase M.E., Davis L., Biggs M.M., Shores-Wilson K., Luther J.F., Niederehe G., Warden D., and Rush A.J. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. 2006. Am. J. Psychiatry 163 (2006) 1531-1541
24. Morris III G.L., and Mueller W.M. Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy. The Vagus Nerve Stimulation Study Group E01-E05. Neurology 53 (1999) 1731-1735
25. Nahas Z., Marangell L.B., Husain M.M., Rush A.J., Sackeim H.A., Lisanby S.H.., Martinez J.M., and George M.S. Two-year outcome for vagus nerve stimulation (VNS) of treatment of major depressive episodes. J. Clin. Psychiatry 66 (2005) 1097-1104
26. Nemeroff C.B., Mayberg H.S., Krahl S.E., McNamara J., Frazer A., Henry T.R., George M.S., Charney D.S., and Brannan S.K. VNS therapy in treatment-resistant depression: clinical evidence and putative neurobiological mechanisms. Neuropsychopharmacology 31 (2006) 1345-1355
27. Nierenberg A.A., Fava M., Trivedi M.H., Wisniewski S.R., Thase M.E., McGrath P.J., Alpert J.E., Warden D., Luther J.F., Niederehe G., Lebowitz B., Shores-Wilson K., and Rush A.J. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am. J. Psychiatry 163 (2006) 1519-1530
28. Oquendo M.A., Baca-Garcia E., Kartachov A., Khait V., Campbell C.E., Richards M., Sackeim H.A., Prudic J., and Mann J.J. A computer algorithm for calculating the adequacy of antidepressant treatment in unipolar and bipolar depression. J. Clin. Psychiatry 64 (2003) 825-833
29. Quitkin F.M., Stewart J.W., McGrath P.J., Nunes E., Ocepek-Welikson K., Tricamo E., Rabkin J.G., and Klein D.F. Further evidence that a placebo response to antidepressants can be identified. Am. J. Psychiatry 150 (1993) 566-570
30. Rush A.J., Giles D.E., Schlesser M.A., Fulton C.L., Weissenburger J., and Burns C. The Inventory for Depressive Symptomatology (IDS); preliminary findings. Psychiatry Res 18 (1986) 65-87
31. Rush A.J., George M.S., Sackeim H.A., Marangell L.B., Husain M.M., Giller C., Nahas Z., Haines S., Simpson Jr. R.K., and Goodman R. Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study. Biol. Psychiatry 47 (2000) 276-286
32. Rush A.J., Fava M., Wisniewski S.R., Lavori P.W., Trivedi M.H., Sackeim H.A., Thase M.E., Nierenberg A.A., Quitkin F.M., Kashner T.M., Kupfer D.J., Rosenbaum J.F., Alpert J., Stewart J.W., McGrath P.J., Biggs M.M., Shores-Wilson K., Lebowitz B.D., Ritz L., Niederehe G., and STAR*D Investigators Group. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control. Clin. Trials 25 (2004) 119-142
33. Rush A.J., Trivedi M., Carmody T.J., Biggs M.M., Shores-Wilson K., Ibrahim H., and Crismon M.L. One-year clinical outcomes of depressed public sector outpatients: a benchmark for subsequent studies. Biol. Psychiatry 56 (2004) 46-53
34. Rush A.J., Marangell L.B., Sackeim H.A., George M.S., Brannan S.K., Davis S.M., Howland R., Kling M.A., Rittberg B.R., Burke W.J., Rapaport M.H., Zajecka J., Nierenberg A.A., Husain M.M., Ginsberg D., and Cooke R.G. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol. Psychiatry. 58 (2005) 347-354
35. Rush A.J., Sackeim H.A., Marangell L.B., George M.S., Brannan S.K., Davis S.M., Lavori P., Howland R., Kling M.A., Rittberg B., Carpenter L., Ninan P., Moreno F., Schwartz T., Conway C., Burke M., and Barry J.J. Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol. Psychiatry 58 (2005) 355-363
36. Rush A.J., Trivedi M.H., Wisniewski S.R., Nierenberg A.A., Stewart J.W., Warden D., Niederehe G., Thase M.E., Lavori P.W., Lebowitz B.D., McGrath P.J., Rosenbaum J.F., Sackeim H.A., Kupfer D.J., Luther J., and Fava M. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry 163 (2006) 1905-1917
37. Rush A.J., Trivedi M.H., Wisniewski S.R., Stewart J.W., Nierenberg A.A., Thase M.E., Ritz L., Biggs M.M., Warden D., Luther J.F., Shores-Wilson K., Niederehe G., Fava M., and STAR*D Study Team. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N. Engl. J. Med. 354 (2006) 1231-1242
38. Russell J.M., Hawkins K., Ozminkowski R.J., Orsini L., Crown W.H., Kennedy S., Finkelstein S., Berndt E., and Rush A.J. The cost consequences of treatment-resistant depression. J. Clin. Psychiatry 65 (2004) 341-347
39. Sackeim H.A. Continuation therapy following ECT: directions for future research. Psychopharmacol. Bull. 30 (1994) 501-521
40. Sackeim H.A. The definition and meaning of treatment-resistant depression. J. Clin. Psychiatry 62 suppl 16 (2001) 10-17
41. Sackeim H.A., Haskett R.F., Mulsant B.H., Thase M.E., Mann J.J., Pettinati H.M., Greenberg R.M., Crowe R.R., Cooper T.B., and Prudic J. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy. JAMA 285 (2001) 1299-1307
42. Sackeim H.A., Rush A.J., and George M.S. Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome. Neuropsychopharmacology 25 (2001) 713-728
43. Sackeim H.A., Brannan S.K., Rush A.J., George M.S., Marangell L.B., and Allen J. Durability of antidepressant response to vagus nerve stimulation (VNS). Int. J. Neuropsychopharmacol. 10 (2007) 817-826
44. Schlaepfer T.E., Frick C., Zobel A., Maier W., Heuser I., Bajbouj M., O'Keane V., Corcoran C., Adolfsson R., Trimble M., Rau H., Hoff H.J., Padberg F., Mülloer-Siecheneder F., Audenaert K., Van den Abbeele D., Stanga Z., and Hasdemir M. Vagus nerve stimulation for depression: efficacy and safety in a European study. Psychol. Med. 38 (2008) 651-661
45. Sheikh, S., Hagan M.C., Adson, D., Rittberg, B., Abuzzahab, F.S., Lee, J.T., Pardo, J.V., 2003. Effects of VNS Therapy on brain metabolism in severe, chronic treatment-resistant depression: one-year outcome. Poster presented at 58th annual scientific convention of the Society of Biological Psychiatry, San Francisco, CA May 15-17.
46. Trivedi M.H., Fava M., Wisniewski S.R., Thase M.E., Quitkin F., Warden D., Ritz L., Nierenberg A.A., Lebowitz B.D., Biggs M.M., Luther J.F., Shores-Wilson K., Rush A.J., and STAR*D Study Team. Medication augmentation after the failure of SSRIs for depression. N. Engl. J. Med. 354 (2006) 1243-1252
47. Trivedi M.H., Rush A.J., Wisniewski S.R., Nierenberg A.A., Warden D., Ritz L., Norquist G., Howland R.H., Lebowitz B., McGrath P.J., Shores-Wilson K., Biggs M.M., Balasubramani G.K., Fava M., and STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry. 163 (2006) 28-40